(E/Z) -Rilzabrutinib
Rilzabrutinib (PRN1008) is an orally active Bruton's tyrosine kinase (BTK) inhibitor with anti-inflammatory and immunomodulatory activities. Rilzabrutinib can be used in the research of various inflammatory and immune-related diseases such as acute respiratory distress syndrome and sepsis[1].
Product Specifications
CAS Number
1575591-66-0
Product Name Alternative
(E/Z) -PRN1008
UNSPSC
12352005
Hazard Statement
H315-H319
Target
Btk
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Smiles
NC1=C2C(C3=C(C=C(OC4=CC=CC=C4)C=C3)F)=NN([C@H]5CN(CCC5)C(/C(C#N)=C/C(C)(N6CCN(C7COC7)CC6)C)=O)C2=NC=N1
Molecular Formula
C36H40FN9O3
Molecular Weight
665.76
Precautions
P264-P280-P302+P352-P362+P364
References & Citations
[1]KR TW, et al. JPWO2021216696A5. 2024-05-01
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Launched
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
bsm-62614R-APC-Cy7 100 µL
Phospho-TAOK 1/2/3 (S181/S181/S177) Recombinant Antibody, APC-Cy7 Conjugated
Sign In for Pricing
View Details 
